+91-8668442535
Home / Biotechnology / High Conte

High Content Screening Market By Product (Instruments, Consumables, Software, Services, Accessories), By Application (Target Identification And Validation, Primary Screening And Secondary Screening, Toxicity Studies, Compound Profiling) - Growth, Share, Opportunities & Competitive Analysis, 2017 – 2025

Global High Content Screening Market by Product (Instruments, Consumables, Software, Services, and Accessories) and Application (Target Identification and Validation, Primary and Secondary Screening, Toxicity Studies, Compound Profiling, and Others) - Market Growth, Future Prospects, and Competitive Analysis, 2017-2025

The most established approach for the multi-parametric analysis of cellular events is high-content screening. For example, the citation 5-cell imaging multi-mode reader combines automated digital wide-field microscopy with conventional multi-mode microplate reading and can capture qualitative information about phenotypic cellular information in a single experiment. It has undergone tremendous technological advancements over the last decade, and HCS imaging systems are expected to evolve continuously throughout the forecast period to offer greater flexibility and meet the requirements of assays involving complex cellular disease models. High-content screening has rising demands for the analysis of 3D spheroids and microtissues and phenotypic assays; it will have a huge impact in the near future on gene editing studies based on CRISP-Cas9.

For the purpose of this study, the various products studied include instruments, consumables, software, services, and accessories. The applications are classified as target identification and validation, primary screening and secondary screening, toxicity studies, compound profiling, and others. Market size estimates and forecasts for these segments are provided in US$ Mn, along with the respective CAGRs for the period 2017-2025, using 2016 as the base year.

The global high-content screening market is segmented geographically into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. 

Market size estimates and forecasts for these segments are provided in US$ Mn, along with the respective CAGRs for the period 2017-2025, using 2016 as the base year.

This report also includes qualitative assessment factors such as market dynamics (drivers, restraints, and opportunities) to have a good understanding of the current and anticipated trends in the global high-content screening market. Competition assessment tools such as Porter’s five forces analysis, market attractiveness assessment, and competitive landscape analysis by key players are also presented in the study. Furthermore, this report concludes with a profile of key market players currently enjoying prominent positions in the global high-content screening market. The key players profiled in this report are Becton Dickinson and Company, Bio-Rad Laboratories, BioTek Instruments Inc., Danaher Corporation, GE Healthcare, Merck Millipore Corporation, Olympus Corporation, Perkin Elmer, Inc., Tecan Group, Yokogawa Electric Corporation.

Based on product, the global high-content screening market is categorized into

  • Instruments
  • Cell Imaging and Analysis System
  • Flow Cytometers
  • Consumables
  • Reagents and Assay kits
  • Microplates
  • Other Consumables
  • Software
  • Services
  • Accessories 

The high-content screening market is driven by factors such as the rising need for cost containment in pharmaceutical research and development and enhanced funding in proteomics. In addition, the technological advancement in the techniques employed, such as flow cytometry, automated imaging technology, and the use of multicolored fluorescence-based reagents, will propel the deep market penetration for high content screening. In 2016, the instrument segment held the largest market share chiefly due to factors such as technological advancement in automation techniques and phenotypic screening and found huge applications in biopharmaceuticals, contract research organizations, research institutes, etc. The software will be the fastest growing market throughout the forecast period 2017-2025, majorly due to its application in obtaining a multi-parametric analysis of cellular events and assisting in obtaining image processing and visualization tools to extract quantitative data from cell populations. The major players in the high content screening market are Becton Dickinson and Company, Bio-Rad Laboratories, BioTek Instruments Inc., Danaher Corporation, GE Healthcare, Merck Millipore Corporation, Olympus Corporation, Perkin Elmer, Inc., Tecan Group and Yokogawa Electric Corporation.

Based on application, the global high-content screening market is categorized into

  • Target Identification and Validation
  • Primary Screening and Secondary Screening
  • Toxicity Studies
  • Compound Profiling
  • Others

The high content screening is witnessing tremendous growth significantly due to the increasing need to launch novel drug molecules owing to the presence of outdated drug therapy regimens with ineffective pharmacodynamic profiles. Additionally, the a burgeoning requirement to promote intensive treatment of chronic diseases such as cardiovascular complications, diabetes, Alzheimer’s, Parkinson’s, cancer, etc. Drug toxicity screening is necessary for new drug application (NDA) and clinical trial approval before the drug enters the market. In 2016, target identification and validation and primary and secondary screening both dominated the market mainly due to factors such as the increasing number of biosimilars and biological drug candidates in the market requiring primary and secondary screening to prove drug efficacy and safety. Additionally, the Hope Act (2013) signed by US government to encourage the development of novel therapies for children with rare diseases will employ target identification and validation to determine the approach for drug discovery and development. The toxicity studies segment is anticipated to register faster growth throughout the forecast period 2017-2025, majorly due to the rising incidence of drug-related adverse events, the increased risk associated with the toxic metabolites produced by the drug biotransformation process, and stringent regulatory norms by USFDA to enhance the drug toxicity screening in the drug clinical trial phase.

For the purpose of this study, the global high-content screening market is categorized into the following regional and country-specific markets:

  • North America
  • US.
  • Canada
  • Europe
  • UK.
  • Germany
  • France
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East and Africa
  • GCC
  • Rest of the Middle East and Africa

North America was observed to be the largest market for high-content screening in the base year 2016. The dominance of North America is mainly attributed to the presence of key pharmaceutical players focusing on novel drug discovery and enhanced government spending in the research and development facilities in healthcare institutions. The market growth in Europe is mainly attributed to the increasing number of patients suffering from rare diseases such as Gaucher disease, Pompe disease, or multiple sclerosis. This factor boosts the demand for phenotypic drug screening and technological advancement in the instruments employed for image analysis and data collection for cellular activities. Asia Pacific was observed as the fastest-growing regional segment throughout the forecast period 2017-2025. Factors that are anticipated to propel the market growth are the presence of a large patient pool that can be enrolled to study drug toxicity studies for drug clinical trials, a competitive market due to the presence of existing major players and evolving biopharmaceutical and medical imaging manufacturers in these regions, and supportive regulatory environment for high content screening products. Moreover, factors such as developing health infrastructure and a public-private partnership between major pharma players and government agencies are going to fuel the rapid growth of the high-content screening market in Latin America and the Middle East and Africa region in the near future.  

Frequently Asked Questions:

The market for High Content Screening is expected to reach US$ 1,988.1 Mn in 2025.

The High Content Screening market is expected to see significant CAGR growth over the coming years,at 5.82%.

The report is forecasted from 2017-2025.What is the base year considered for High Content Screening Market?

The base year of this report is 2016.

Becton Dickinson and Company,Bio-Rad Laboratories Inc.,BioTek Instruments, Inc.,Danaher Corporation,GE Healthcare are some of the major players in the global market.

Choose License Type
Trusted By
Godaddy
Published Date:  Aug 2017
Category:  Biotechnology
Report ID:   58619
Report Format:   PDF
Pages:   120
Rating:    4.5 (60)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
+91-8668442535
24/7 Research Support